Acute myeloid leukemia is a fast-moving blood cancer that demands immediate medical attention.
In short: Acute myeloid leukemia is a cancer of the blood and bone marrow that progresses rapidly if left untreated. By crowding out healthy cells, it disrupts the body's ability to produce essential red cells, white cells, and platelets, often mimicking the symptoms of a persistent, severe flu.
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults. It originates in the bone marrow, where blood stem cells fail to mature properly. Instead of developing into functional red blood cells, platelets, or white blood cells, these cells become abnormal myeloblasts. As these leukemia cells proliferate, they physically crowd out healthy marrow, leaving insufficient space for the production of essential blood components. This depletion leads to clinical manifestations such as anemia, increased infection risk, and easy bleeding or bruising.
The disease is complex, with various subtypes defined by the maturity of the cancer cells and specific genetic mutations. For instance, acute promyelocytic leukemia (APL) involves a distinct chromosomal translocation that prevents white blood cell maturation, creating a high risk of severe bleeding and clotting. While many cases of AML arise without identifiable causes, known risk factors include exposure to radiation, certain chemicals like benzene, previous chemotherapy, and pre-existing blood disorders such as myelodysplastic syndrome. Age and male gender are also associated with higher risk.
Diagnosis typically involves analyzing blood and bone marrow samples through procedures like complete blood counts, peripheral blood smears, and flow cytometry. Because AML progresses quickly—often showing symptoms just weeks before a formal diagnosis—early intervention is critical. Treatment strategies are highly personalized, often involving chemotherapy to induce remission, followed by additional therapies or stem cell transplants. Advances in the field have introduced targeted inhibitors for specific genetic pathways, significantly expanding the therapeutic landscape for patients facing this aggressive condition.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Acute Myeloid Leukemia Treatment
- Also: Acute myeloid leukemia
To cite this card, link to https://intellectplus.co.uk/app/health-acute-myeloid-leukemia.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health, medicine and disease · More in Health · Latest · A–Z · All topics
